Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 4Phase NA 2Phase 3 1Phase 2/3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 374Neoplasms 325Neoplasm Metastasis 289Leukemia, Myeloid, Acute 282Breast Neoplasms 276Colorectal Neoplasms 238Melanoma 196Ovarian Neoplasms 192Recurrence 185Multiple Myeloma 180Prostatic Neoplasms 157Pancreatic Neoplasms 156Lung Neoplasms 156Squamous Cell Carcinoma of Head and Neck 150Lymphoma, Non-Hodgkin 145Glioblastoma 145Triple Negative Breast Neoplasms 119Myelodysplastic Syndromes 117Carcinoma, Renal Cell 111Stomach Neoplasms 110Advanced Solid Tumors 108Glioma 107Precursor Cell Lymphoblastic Leukemia-Lymphoma 104Brain Neoplasms 104Lymphoma 103Lymphoma, Large B-Cell, Diffuse 102Lymphoma, B-Cell 98Carcinoma, Hepatocellular 95Endometrial Neoplasms 92Lymphoma, Follicular 90

Interventions

Taxes 1Metformin 1Gemcitabine 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Pancreatic Adenocarcinoma × 1 year × Clear all
NCT02336087 2026-02-04

Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery

City of Hope Medical Center

Phase 1 Active not recruiting
21 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡